Esperovax Awarded Subcontract for Development of Thermostable Oral Vaccine Platform
Esperovax, Inc., a private Michigan-based biotechnologycompany specializing in innovative circular RNA technologies announced today that DynPort VaccineCompany LLC (DVC), a General Dynamics Information Technology (GDIT) company, awarded Esperovax atwo-year base subcontract valued at $1.5 million for the pre-clinical development of an oral H5N1 influenzaRNA vaccine. This subcontract entitled “An oral, encapsulated yeast-based vaccine platform for…
Read MoreEsperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative
Esperovax, a U.S.-based preclinical biopharmaceutical company and a BLUE KNIGHT™ resident company, is receiving an award for $ 1 M to further develop a yeast-based oral COVID-19 RNA vaccine candidate as part of the BLUE KNIGHT™ QuickFire Challenge: Accelerating Project NextGen. This award will support critical studies aimed at demonstrating vaccine safety and immunoprotection in…
Read MoreEsperovax Appoints Dr. Robin Robinson as President and CEO
Plymouth, Mich. – Esperovax, Inc. a leading oral RNA vaccine and therapeutic technology company specializing in oral mRNA-based medicines, announced today the appointment of Dr. Robin Robinson as President and Chief Executive Officer (CEO). Dr. Robinson will lead the company from technology discovery and early development into the next stages of pre-clinical/ clinical product development and…
Read MoreEsperovax, Ginkgo Bioworks Join Hands To Develop Circular RNA-based Therapeutics
Esperovax, a developer of oral mRNA biologics, and Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, Thursday announced a partnership to develop circular RNAs for a variety of therapeutic applications. Initially, Ginkgo and Esperovax would work to develop circRNAs harboring payloads to specifically target colorectal cancer by inducing cell…
Read MoreEsperovax Signs Exclusive Licensing Agreement with the University of Michigan for a Novel Manufacturing Technology for the Production of Vaccines and Therapeutics
Initiative to enable continuous oral vaccine and therapeutics manufacturing for diseases worldwide ANN ARBOR, Mich. — Esperovax, a leading developer of oral vaccines, today announced it has signed a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based manufacturing method. This next-generation manufacturing…
Read MoreEsperovax and Life Magnetics to Deliver New Oral Therapeutic to Colorectal Patients
Esperovax, a leading developer of oral mRNA biologics, and Life Magnetics, Inc., creators of RNA stabilization technology, today announced the signing of an agreement to co-develop an innovative new oral RNA therapeutic delivery system for colorectal cancer patients that can be stored at room temperature. Oral and room temperature delivery of RNA therapeutics is a…
Read More
Esperovax Selected as a
BLUE KNIGHT™ Company
Aiming to accelerate research on groundbreaking oral mRNA vaccine platform [San Francisco/California] — Esperovax, a leading developer of oral mRNA vaccines, announced it has been selected as a BLUE KNIGHT™ company. Blue Knight is a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), part of…
Read MoreGlobal Thermostable Vaccines and Thermostable Biologics Market to 2035 – by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region – ResearchAndMarkets.com
DUBLIN, February 08, 2022–(BUSINESS WIRE)–The “Thermostable Vaccines and Thermostable Biologics Market by Type of Molecule, Target Indications, Type of Therapy, Key Players, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current market landscape and future opportunities for the players involved in the…
Read MoreEsperovax Co-Founders Published in Separation and Purification Technology Journal
Co-Authored piece examines Aques Two-Phase System aimed at speeding vaccination production, quick deployment for today’s healthcare needs Plymouth, Michigan, May 15, 2021 – Esperovax a company dedicated to bringing rapid deployment of oral vaccines to stop the spread of infectious disease announces a co-authored article, “Continuous Purification of an Enveloped and Non-enveloped Viral Particle Using an…
Read MoreMichigan Rise Invests in Esperovax
Biotech Company developing Novel Oral mRNA–Based vaccines and biotherapeutics East Lansing, MI – Michigan Rise is pleased to formally introduce Esperovax, developer of the Egress RD™ Oral Biologics platform, to its growing portfolio. The Plymouth, Michigan-based company has developed a novel, mRNA-based oral vaccine platform that will enable large-scale production and distribution of shelf-stable vaccines…
Read More